AbelZeta Pharma is a global clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative cell therapies for diseases with significant unmet medical needs. The company develops proprietary T-cell-based therapeutics designed to harness the body’s immune system to treat hematologic malignancies, inflammatory and immunological diseases, and solid tumors.

With centers in Rockville, Maryland, and Shanghai, AbelZeta advances a pipeline of CAR-T therapies through research, early-stage clinical development, and manufacturing at its own GMP facilities. Its development approach uses early clinical proof-of-concept data to identify and rapidly advance promising candidates, with the goal of delivering more precise and effective treatments to patients worldwide.